PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December
(firmenpresse) - BEVERLY HILLS, CA -- (Marketwired) -- 10/27/14 -- PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a registered US Veterinary Pharmaceutical company, today announced it has signed an agreement with AllCells to start a pre-clinical study on its major product Escozine for Pets™ with the most common canine cancer tumor cell lines (lymphoma and osteosarcoma). Results are expected in December, after which the Company will announce the conclusions as well as post the Study''s final report on its website.
Escozine for Pets™ contains a patented, high-potency bioactive anti-cancer compound, which the Company believes enables the expanding Escozine for Pets product line to become one of the leading medications and nutraceutical products for the treatment and prevention of cancer in companion animals as well as livestock.
PetLife has engaged Alameda, California-based AllCells, founded in 1998, for its reputation as a leading, global provider of advanced cellular research to academic and industrial research laboratories, government institutions, and pharmaceutical companies throughout North America, Europe, Asia and Japan.
As stated in the AllCells'' Statement of Work, the canine tumor cell lines will be treated with Escozine for Pets™ and, using flow cytometry, samples will be analyzed for apoptosis (cell death) and necrosis at 48 and 72-hour intervals. The cell count and percent of apoptosis and necrosis will be calculated to determine the product''s efficacy. The University of California, Davis, will be providing the osteosarcoma cell line for this study.
PetLife''s sister company, Medolife Corp., previously has conducted pre-clinical studies with its similar product, ''Escozine for humans'' on human cancer cell lines at the University of California, San Diego''s Moores Cancer Center and received positive results. Those results showed up to 95 percent apoptosis of cancer cells when using Escozine, as well as positive synergistic effects when combined with a variety of traditional chemotherapy treatments.
Animal cancer cells respond to anti-cancer drugs the same as do human cancer cells. PetLife anticipates that the AllCells study will show similar results in the canine cancer cell lines. Upon completion of the study, PetLife will begin preparing its application for the FDA trials of its veterinary prescription strength Escozine for Pets products.
.
AllCells () is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease, and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. AllCells is fully certified in accordance with local, state and federal requirements.
PetLife () is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and a spinoff of Medolife Corp.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented ''Escozine for humans'' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife''s mission is to bring its new, scientifically proven, non-toxic, high potency bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at . Statements released by PetLife that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company''s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company''s business prospects and performance. The company''s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company''s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.
Sebastian Serrell-Watts
T: (310) 279-5154
E:
MZ Group
Ted Haberfield
President
T: 760-755-2716
E:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.10.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 1312880
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BEVERLY HILLS, CA
Phone:
Kategorie:
Livestock
Anmerkungen:
Diese Pressemitteilung wurde bisher 316 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December
"
steht unter der journalistisch-redaktionellen Verantwortung von
PetLife Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
